Corvus Signals Broad Ambition with Fortified Finances and Pipeline Push

SOUTH SAN FRANCISCO, Calif. – August 06, 2026 – In a clear signal of sustained momentum, Corvus Pharmaceuticals today detailed a multi-front clinical expansion for its lead drug candidate, soquelitinib, backed by a formidable balance sheet that provides an operational runway into the second quarter of 2028. The clinical-stage biopharmaceutical company’s second-quarter update reveals that its strategy to leverage soquelitinib across a spectrum of difficult-to-treat diseases—from a rare T-cell cancer to common inflammatory conditions like atopic dermatitis—is not just on track, but accelerating.

This aggressive push is fueled by a robust cash position of $215.2 million, largely the result of a successful financing round earlier this year that netted nearly $190 million. The influx of capital is enabling Corvus to manage a deliberate increase in research and development spending, which doubled year-over-year to $16.0 million for the quarter. Rather than a sign of distress, this increased burn rate is a direct indicator of the company's confidence and its commitment to advancing multiple, high-stakes clinical programs simultaneously.

“We believe soquelitinib, our oral, selective ITK inhibitor, is well positioned as a potential new treatment paradigm for patients across a broad range of diseases, based on a novel mechanism that rebalances the immune system,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. The company’s latest update provides tangible evidence of this strategy in action, with key trials progressing and new studies on the horizon.

A Pipeline with a Singular Focus: Soquelitinib's Expanding Reach

At the heart of Corvus's strategy is soquelitinib, an investigational oral drug designed to selectively inhibit Interleukin-2-inducible T-cell kinase (ITK). The company is driving enrollment in two critical trials that could define the drug’s future. The first is a registrational Phase 3 trial for relapsed or refractory peripheral T-cell lymphoma (PTCL), a group of aggressive cancers with dire prognoses and no fully approved treatments in the relapsed setting. The FDA has already granted soquelitinib both Orphan Drug and Fast Track designations for PTCL, underscoring the urgent unmet need. The randomized trial (NCT06561048) is comparing the drug against standard chemotherapy, with an interim futility analysis expected in the first quarter of 2027.

Simultaneously, Corvus is advancing a Phase 2 trial, SIERRA1, for moderate-to-severe atopic dermatitis (AD), a chronic skin condition affecting millions. This 200-patient study is evaluating several doses against a placebo, with topline results anticipated in the third quarter of 2027. The company’s ambitions don’t stop there. Corvus announced plans to initiate a Phase 1b trial in hidradenitis suppurativa and a Phase 2 trial in asthma later this year, further broadening the drug's potential applications in the massive immunology and inflammation market.

The Science of Rebalancing: ITK Inhibition's Promise

The scientific rationale underpinning this broad pipeline is the unique mechanism of ITK inhibition. ITK is a key enzyme in T-cells, which orchestrate the body's immune response. By selectively inhibiting ITK, soquelitinib is believed to dial down the pro-inflammatory Th2 and Th17 T-cell pathways implicated in autoimmune diseases like atopic dermatitis, while preserving the Th1 pathway crucial for fighting tumors and infections. This ability to 'rebalance' the immune system, rather than broadly suppressing it, is a key differentiator.

Compelling evidence supporting this mechanism was presented at the recent Society for Investigative Dermatology (SID) annual meeting. Final data from a Phase 1 study in atopic dermatitis patients showed significant clinical benefit. In the cohort with the longest treatment duration, 75% of patients on soquelitinib achieved a 75% improvement in the Eczema Area and Severity Index (EASI-75), a key clinical endpoint, compared to just 20% on placebo. Critically, the drug was well-tolerated, with no serious adverse events and, notably, no cases of conjunctivitis, a side effect seen with some other advanced AD therapies.

"The ability to precisely modulate T-cell function without inducing broad immunosuppression is a significant goal in immunology," noted one clinical immunologist not involved with the company. "The data for ITK inhibition in atopic dermatitis is compelling because it suggests a path toward potent efficacy with a favorable safety profile, which is the combination that both patients and physicians are looking for."

Financial Fuel for an Ambitious Agenda

Executing a multi-indication strategy with several late-stage trials is a capital-intensive endeavor. Corvus's current financial strength is the critical growth signal that makes its ambitious plans credible. The $215.2 million in cash and marketable securities as of June 30, 2026, provides a clear runway into the second quarter of 2028. This financial stability allows the company to pursue its development plans from a position of strength, funding the expanded clinical trial costs without immediate pressure to seek additional capital.

The company’s net loss widened to $18.0 million for the quarter, up from $8.0 million in the prior year, directly reflecting the costs of running the Phase 3 PTCL and Phase 2 AD trials. For a clinical-stage biotech, such an increase in R&D spending is an expected and often positive indicator, representing direct investment into assets that, if successful, will create significant long-term value.

A Strategic Bridge to the East

Further amplifying its growth strategy is Corvus's collaboration with its Chinese partner, Angel Pharmaceuticals. Corvus, which holds a 49% equity stake in Angel Pharma, is leveraging the partnership to accelerate soquelitinib’s development and tap into the vast Chinese market. Angel Pharma is currently enrolling a parallel Phase 1b/2 trial of soquelitinib for atopic dermatitis in China, with initial data expected by the end of this year. This collaboration not only provides a second stream of clinical data but also speeds up overall patient enrollment.

Corvus underscored its commitment to this strategy by participating in Angel Pharma's recent financing, investing $5.0 million. This capital will help fund Angel's ongoing AD trial and support the initiation of a new Phase 2 trial for soquelitinib in asthma, planned for early 2027. This dual-hemisphere approach could allow Corvus to combine data sets, potentially accelerating the timeline for a global Phase 3 program in atopic dermatitis and solidifying soquelitinib's position as a worldwide asset.